Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
NCT03672136Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03672136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672136.